Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston

Canada NewsWire August 6, 2014

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market

Canada NewsWire August 5, 2014

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014

Canada NewsWire July 31, 2014

SCRA Announces First Tenant for Nexton Property

Business Wire July 7, 2014

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

Canada NewsWire June 11, 2014

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company

Canada NewsWire June 10, 2014

Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer

Canada NewsWire June 2, 2014

Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO

Canada NewsWire May 22, 2014

Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders

Canada NewsWire May 12, 2014

Aeterna Zentaris Announces At the Market Issuance Program

Canada NewsWire May 9, 2014

Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results

Canada NewsWire May 8, 2014

Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations

Canada NewsWire May 5, 2014

Aeterna Zentaris to Announce First Quarter 2014 Financial and Operating Results on May 8, 2014 and Hold Annual Shareholders Meeting on May 9, 2014

Canada NewsWire April 30, 2014

Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors

Canada NewsWire April 9, 2014

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego

Canada NewsWire April 1, 2014

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs

Canada NewsWire March 28, 2014

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results

Canada NewsWire March 20, 2014

AEterna Zetaris (T.AEZ) dips 10% in anticipation of 2013 year-end results

Gaalen Engen March 12, 2014

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014

Canada NewsWire March 12, 2014

Pluristem Therapeutics Granted New Patent amid Positive Clinical Trial

Accesswire February 21, 2014